ChemGenex completes SPP
Tuesday, 14 October, 2008
ChemGenex Pharmaceuticals [ASX: CXS] has completed its share placement program, raising over $13 million to fund the late-stage development of its omacetaxine candidate for chronic myeloid leukaemia.
15.3 million shares were placed during the program, trading at 85 cents each. During the period of the program, CXS shares traded at a high of 83 cents and a low of 72.5 cents.
All shares on offer were purchased. ChemGenex representatives said they were pleased the placement went so well considering the unstable global financial climate.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
